key: cord-0703752-hux4o9dd
authors: Yacouba, Abdourahamane; Lagaré, Adamou; Maiga, Daouada Alhousseini; Sambo, Halimatou Moumouni; Ousmane, Sani; Harouna, Zelika Hamidou; Marou, Boubacar; Sanoussi, Maman K.; Aoula, Balki; Amadou, Ali; Boureima, Hassane; Amatagas, Saidou; Ousmane, Abdoulaye; Adehossi, Eric; Mamadou, Saidou
title: Laboratory organisation and management of SARS-CoV-2 infection in Niger, West Africa
date: 2020-12-21
journal: Afr J Lab Med
DOI: 10.4102/ajlm.v9i1.1308
sha: 4109f16b41354be2f147de02554e33d6922e33e1
doc_id: 703752
cord_uid: hux4o9dd

BACKGROUND: As the coronavirus disease 2019 (COVID-19) pandemic unfolds, laboratory services have been identified as key to its containment. This article outlines the laboratory organisation and management and control interventions in Niger. INTERVENTION: The capitol city of Niger, Niamey, adopted a ‘National COVID-19 Emergency Preparedness and Response Plan’ to strengthen the preparedness of the country for the detection of severe acute respiratory syndrome coronavirus-2. Laboratory training and diagnostic capacity building were supported by existing active clinical and research laboratories for more rapid and practicable responses. The National Reference Laboratory for Respiratory Viruses located at the Centre de Recherche Médicale et Sanitaire was designated as the reference centre for COVID-19 testing. The national plan for COVID-19 testing is being gradually adopted in other regions of the country in response to the rapidly evolving COVID-19 emergency and to ensure a more rapid turn-around time. LESSONS LEARNT: After the decentralisation of COVID-19 testing to other regions of the country, turn-around times were reduced from 48–72 h to 12–24 h. Reducing turn-around times allowed Niger to reduce the length of patients’ stays in hospitals and isolation facilities. Shortages in testing capacity must be anticipated and addressed. In an effort to reduce risk of shortages and increase availability of reagents and consumables, Niamey diversified real-time reverse transcriptase–polymerase chain reaction kits for severe acute respiratory syndrome coronavirus-2 detection. RECOMMENDATIONS: Continued investment in training programmes and laboratory strategy is needed in order to strengthen Niger’s laboratory capacity against the outbreak.

Read online:

Scan this QR code with your smart phone or mobile device to read online.

declaration of the index case, a total of 980 cases have been confirmed as of 15 June 2020. 5 As this pandemic unfolds, laboratory services have been identified as key to containment efforts. This article outlines the laboratory organisation and management and control interventions in Niger.

This article followed all ethical standards for research without direct contact with human or animal subjects.

Severe acute respiratory syndrome coronavirus-2 is an emerging respiratory pathogen spreading rapidly through the general population. Niamey, the capitol city of Niger, adopted the 'National COVID-19 Emergency Preparedness and Response Plan' (available from https://tinyurl.com/ y2x3vpmt) to strengthen Niger's preparedness for the detection of SARS-CoV-2. This plan details the procedures for containment, contact tracing and screening based on the risk of spread. The plan is structured around five major strategic axes including reinforcement of coordination, strengthening of epidemiological surveillance, strengthening of health services capacities, reinforcement of risk communication and community engagement, and, lastly, the creation of isolation facilities. Gradually, the national plan on COVID-19 testing is being adopted in other regions of the country in response to the rapidly evolving COVID-19 emergency and to ensure a more rapid turn-around time (TAT). This adoption involves gradual decentralisation of the SARS-CoV-2 RNA rRT-PCR assays to three regions, Tahoua, Maradi and Zinder, located 550, 662 and 891 kilometres from Niamey ( Figure 1 ). The choice of these regions was based on several factors, including COVID-19, coronavirus disease 2019; PCR, polymerase chain reaction; SARS-CoV-2, severe acute respiratory coronavirus-2. the distance from the capital city, the number of close contacts in these regions, the number of confirmed cases at the time of the decentralisation and the capacity of the laboratory facilities on site.

The Tahoua laboratory analysed samples collected from the Tahoua and Agadez regions. Samples collected from the Zinder and Diffa regions were analysed in Zinder, whereas the Maradi laboratory analysed samples collected in the Maradi region. Samples collected from the Niamey, Dosso and Tillabery regions were analysed at CERMES. Logistics and testing capacity are handled by CERMES, which reported the availability of the reagents and materials needed to sample patients and to perform the rRT-PCR on a weekly basis to the Ministry of Health.

Severe acute respiratory syndrome coronavirus-2 is classified as a Risk Group 3 human pathogen, similar to Middle East respiratory syndrome coronavirus and severe acute respiratory syndrome coronavirus. 6 The interim guidance from the World Health Organization suggests that nonpropagative processing and handling of specimens containing SARS-CoV-2 must be performed in standard biosafety level-2 laboratories. 7, 8 Consequently, Niamey leveraged the safe practices and techniques, safety equipment and appropriate facility design of CERMES to reduce or eliminate exposure of laboratory workers to SARS-CoV-2containing materials according to the World Health Organization requirements. 7 Before the decentralisation of SARS-CoV-2 RNA rRT-PCR assays to other regions, samples collected from across the country were sent to CERMES. Samples from remote regions such as Diffa, Zinder and Agadez were transported using flights in accordance with category B transportation regulations. 9 In an effort to help close contact management, sample collection was performed during home visits.

Ribonucleic acid extraction from samples was performed manually using QIAamp ® Viral RNA Mini Kit (250) (QIAGEN GmbH, Hilden, Germany) or Nucleic Acid Isolation or Purification Reagent (DaAn Gene Co., Ltd, Guangzhou, China) according to the manufacturer's instructions. Two teams of four laboratory technicians were dedicated to RNA extraction at CERMES. These teams were often overworked due to the large volume of samples handled.

Qualitative rRT-PCR assays were performed using the nucleic acid testing kit (DaAn Gene Co., Ltd, Guangzhou, China). 10 Two target genes, the open reading frame1ab (ORF1ab) and nucleocapsid protein (N), were simultaneously amplified. A cycle threshold value lower than 40 was defined as a positive test result, and a cycle threshold value of 40 or more was defined as a negative outcome according to the manufacturer's protocol. Alternatively, rRT-PCR targeting the RdRp gene of the SARS-CoV-2 or SARS-like coronavirus was performed using the LightMix ® Modular SARS-CoV-2 RdRp (TIB Molbiol, Berlin, Germany). Positive samples for RdRp gene were confirmed by performance of rRT-PCR for the detection of the E gene using LightMix ® SarbecoV E gene plus equine arteritis virus control (TIB Molbiol, Berlin, Germany). Given the extraordinary demand for reagents and consumables, risk of supply shortages became the main issue. Niamey experienced a shortage of RNA extraction kits and this led to the prioritisation of the testing of vulnerable people, health professionals and patients requiring hospitalisation.

COVID-19, coronavirus disease 2019; SARS-CoV-2, severe acute respiratory coronavirus-2. As of 15 June 2020, a total of 5386 samples had been tested for SARS-CoV-2 in Niger. Of these, 980 (18.2%) were confirmed positive ( Figure 2 ). All test results, positive or negative, were immediately reported to the national committee, which is responsible for communication on the pandemic. The highest number of new daily confirmed cases (68 cases) was detected on 11 April 2020.

In March and April 2020, before the decentralisation of SARS-CoV-2 RNA rRT-PCR assays to other regions, the number of samples received exceeded the capacity of the single centralised laboratory earmarked for the testing. Consequently, TATs were between 48 h and 72 h. This TAT length often created a disconnect between clinicians and laboratory staff. Indeed, according to the clinicians, the TAT of 48-72 h delayed treatment and increased patients' length of stay, particularly in isolation facilities where patients are often asymptomatic. After decentralisation, on 15 June, 2020, the TAT had decreased significantly to 12 h at Maradi and between 12 h and 24 h at Tahoua, Zinder and CERMES, Niamey.

Experience gained in the management of previous outbreaks (Rift Valley Fever and meningitis) helped Niamey to build a quick response to the COVID-19 pandemic. However, additional control efforts are needed to improve the laboratory strategy and response against COVID-19 in the country. Firstly, a well-coordinated laboratory strategy and operational plan is needed in order to address the shortcomings of the existing plan. Moreover, considering the importance of improved SARS-CoV-2 laboratory capacity, the country should provide extensive training to laboratory technicians in preparation for rapid expansion of laboratory diagnostic capacity. Secondly, laboratory TAT is critical in determining the success of both the laboratory response programme and the management of patients. Reducing the TAT allowed reductions in patients' length of stay in hospitals and isolation facilities. Thirdly, communication between clinical and laboratory staff needs to be improved in order to ensure that laboratory results are understandable to clinicians.

Fourthly, the shortages in testing capacity need to be anticipated and addressed. If capacity is exceeded, priority should be given to the testing of vulnerable patients, health professionals and patients requiring hospitalisation. Niamey diversified rRT-PCR kits for SARS-CoV-2 detection to reduce the risk of shortages and increase the availability of reagents. It has been demonstrated that RNA extraction kits from different manufacturers are interchangeable. 11 However, diversifying the type of rRT-PCR kits for SARS-CoV-2 detection can lead to some variation in the detection rate between kits. 12 It has been well documented that the limit of detection of different rRT-PCR kits can differ substantially. 13, 14 Therefore, care must be taken in the interpretation of the results when using different kits for the monitoring of patients. Fifthly, the overwhelming number of specimens to test highlighted the need for fast methods to extract viral RNA. Ribonucleic acid extraction from samples was performed manually in Niger. In addition to the high risk of contamination, manual extraction of viral RNA is time consuming and requires a large number of laboratory professionals.

Lastly, amplification of multiple target genes (e.g. N, E, RpRd genes) could be used to avoid invalid results and increase sensitivity for detection of new genomic variants. 15, 16 Recommendations Despite TAT improvement in the laboratory management of COVID-19 testing, several additional control efforts are needed to improve the laboratory response against COVID-19 in Niger. Considering the importance of improved SARS-CoV-2 laboratory capacity, continued investment in training programmes and laboratory strategy is needed to systematically guide the laboratory response against the outbreak.

Coronavirus disease named Covid-19

WHO Director-General's opening remarks at the media briefing on COVID-19 -25

The species severe acute respiratory syndrome-related coronavirus: Classifying 2019-nCoV and naming it SARS-CoV-2

World Health Organisation. Coronavirus disease (COVID-19) situation reports

Niger enregistre son premier cas

Safety considerations in the laboratory testing of specimens suspected or known to contain the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

World Health Organisation. Laboratory testing for coronavirus disease 2019 (COVID-19) in suspected human cases: Interim guidance

World Health Organization

World Health Organization

World Health Organisation. Guidance on regulations for the transport of infectious substances

World Health Organisation. WHO emergency use listing for in vitro diagnostics (IVDs) detecting SARS-CoV-2 nucleic acid

A novel strategy for community screening of SARS-CoV-2 (COVID-19): Sample pooling method

Comparison of seven commercial RT-PCR diagnostic kits for COVID-19

Comparison of the panther fusion and a laboratory-developed test targeting the envelope gene for detection of SARS-CoV-2

Limits of detection of 6 approved RT-PCR kits for the novel SARS-coronavirus-2 (SARS-CoV-2)

Real-time RT-PCR in COVID-19 detection: Issues affecting the results

Multiple assays in a real-time RT-PCR SARS-CoV-2 panel can mitigate the risk of loss of sensitivity by new genomic variants during the COVID-19 outbreak

Authors would like to acknowledge the contributions of the National COVID-19 Emergency Preparedness and Response Committee for the technical, resource and logistical contributions, the government of Niger, the Ministry of Health and all its partners for the good support that formed the basis of a favourable working environment for the response against COVID-19 pandemic in Niger. We would also like to thank Dr Ahmed Olowo-Okere of Usmanu Danfodiyo University, Sokoto-Nigeria, for language editing.

The authors have declared that no competing interests exist.

A.Y. and S.M. conceived and designed the study. 

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

The data are available from the corresponding author upon reasonable request.

The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of any affiliated agency of the authors.